185 related articles for article (PubMed ID: 17762662)
1. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
[TBL] [Abstract][Full Text] [Related]
3. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
Malmqvist K; Kahan T; Edner M; Held C; Hägg A; Lind L; Müller-Brunotte R; Nyström F; Ohman KP; Osbakken MD; Ostergern J
J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
Am J Hypertens; 2002 May; 15(5):389-93. PubMed ID: 12022239
[TBL] [Abstract][Full Text] [Related]
5. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
Nyström F; Malmqvist K; Ohman KP; Kahan T
J Hypertens; 2002 Aug; 20(8):1527-33. PubMed ID: 12172314
[TBL] [Abstract][Full Text] [Related]
6. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Schiffrin EL; Park JB; Pu Q
J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
[TBL] [Abstract][Full Text] [Related]
7. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
8. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
von zur Mühlen B; Kahan T; Hägg A; Millgård J; Lind L
J Hypertens; 2001 Oct; 19(10):1813-8. PubMed ID: 11593101
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman KP; Nyström F; Hägg A; Lind L;
J Hypertens; 2001 Oct; 19(10):1783-7. PubMed ID: 11593098
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol.
Makris TK; Stavroulakis GA; Krespi PG; Hatzizacharias AN; Triposkiadis FK; Tsoukala CG; Votteas VV; Kyriakidis MK
Am J Hypertens; 2000 Jul; 13(7):783-8. PubMed ID: 10933570
[TBL] [Abstract][Full Text] [Related]
11. Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
Schiffrin EL
Can J Cardiol; 2002 May; 18 Suppl A():15A-18A. PubMed ID: 12045789
[TBL] [Abstract][Full Text] [Related]
12. The importance of left ventricular hypertrophy in human hypertension.
Kahan T
J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
[TBL] [Abstract][Full Text] [Related]
13. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
Stumpe KO; Haworth D; Hoglund C; Kerwin L; Martin A; Simon T; Masson C; Kassler-Taub K; Osbakken M
Blood Press; 1998 Jan; 7(1):31-7. PubMed ID: 9551875
[TBL] [Abstract][Full Text] [Related]
15. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy.
Galderisi M; Cicala S; De Simone L; Caso P; Petrocelli A; Pietropaolo L; Celentano A; Mininni N; de Divitiis O
Ital Heart J; 2001 Sep; 2(9):677-84. PubMed ID: 11666096
[TBL] [Abstract][Full Text] [Related]
16. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
[TBL] [Abstract][Full Text] [Related]
17. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.
Brilla CG; Funck RC; Rupp H
Circulation; 2000 Sep; 102(12):1388-93. PubMed ID: 10993857
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.
Ambrose J; Pribnow DG; Giraud GD; Perkins KD; Muldoon L; Greenberg BH
J Cardiovasc Pharmacol; 1999 Mar; 33(3):433-9. PubMed ID: 10069680
[TBL] [Abstract][Full Text] [Related]
19. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
